Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CanniMed Therapeutics was a pioneering Canadian biopharmaceutical company focused on the production and development of pharmaceutical-grade medical cannabis. Originally established as Prairie Plant Systems in 1988, the company became the first licensed producer under Health Canada's medical marijuana regulations. CanniMed specialized in standardized cannabis products, including oils and dried flower, supported by clinical research for indications such as chronic pain and neurological conditions. The company was acquired by Aurora Cannabis in 2018 for approximately $1.1 billion CAD, marking a significant consolidation in the medical cannabis sector.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on CVTFF Pharmaceuticals.